Efficacy

CONTACT GSK 1-XXX-XXX-XXXX

Learn more about efficacy

Explore the clinical data about once-daily TRELEGY

TRELEGY is approved for reducing exacerbations in patients with a history of COPD exacerbations.

10,000+ PATIENTS

Symptomatic patients with at least 1 COPD exacerbation in the last year while on maintenance medication1,2*

52-WEEK STUDY

A randomized, double-blind, 3-arm, parallel group; primary endpoint measured was the annual rate of moderate to severe exacerbations

1ST AND ONLY

First and only trial to study the efficacy and safety of triple therapy vs an ICS/LABA and vs a LAMA/LABA in an exacerbating COPD population

Exacerbation severity criteria: Moderate if treatment with systemic corticosteroids and/or antibiotics was required and severe if hospitalization was required.

*Eligible patients were symptomatic with a postbronchodilator percent predicted FEV1 <50% and a history of 1 or more moderate or severe exacerbations within the previous year, or with a postbronchodilator percent predicted FEV1 of 50% to 80% and a history of 2 or more moderate exacerbations or 1 severe exacerbation in the previous year. At screening, patients (mean age: 65 years) had a mean postbronchodilator percent predicted FEV1 of 45.5% and a mean postbronchodilator FEV1/FVC ratio: 0.47.

FEV1=forced expiratory volume in 1 second; FVC=forced vital capacity.

IMPACT TRIAL: DESIGNED TO REFLECT CLINICAL PRACTICE

Current maintenance medications included ICS + LABA + LAMA (34%), ICS + LABA (26%), LAMA + LABA (8%), LAMA (7%), and other (25%).

Each delivered once daily via its respective ELLIPTA inhaler.

FF=fluticasone furoate; UMEC=umeclidinium; VI=vilanterol.

In the landmark IMPACT trial,

TRELEGY was proven the most effective treatment for reducing moderate to severe exacerbations vs FF/VI (an ICS/LABA) and vs UMEC/VI (a LAMA/LABA).

Primary Endpoint: Annual rate of moderate to severe exacerbations2

Keep samples on hand to get patients started on TRELEGY

REQUEST SAMPLES

In the landmark IMPACT trial,

TRELEGY significantly improved lung function2 vs FF/VI (an ICS/LABA) and vs UMEC/VI (a LAMA/LABA) in patients with a history of COPD exacerbations

Secondary Endpoint: Change from baseline in trough FEV1 at month 12 vs FF/VI (an ICS/LABA)

FEV1=forced expiratory volume in 1 second

Secondary Endpoint: Change from baseline in trough FEV1 at month 12 vs UMEC/VI (an LAMA/LABA)

FEV1=forced expiratory volume in 1 second

Keep samples on hand to get patients started on TRELEGY

REQUEST SAMPLES

TRELEGY significantly improved health-related quality of life

in patients with a history of COPD exacerbations

Patients taking TRELEGY were more likely to show an improvement in health-related quality of life total score at 1 year vs FF/VI and vs UMEC/VI as measured by the SGRQ.2,3*

Responder rate* was statistically significantly greater for TRELEGY.2

*Response defined as a decrease in SGRQ total score from baseline of 4 or more. SGRQ for COPD (SGRQ-C) was used and results were then converted to SGRQ for reporting purposes.

SGRQ=St George's Respiratory Questionnaire

Find a TRELEGY representative in your area and request a visit

REQUEST A REP
Exacerbations

In the landmark IMPACT trial,

TRELEGY was proven the most effective treatment for reducing moderate to severe exacerbations vs FF/VI (an ICS/LABA) and vs UMEC/VI (a LAMA/LABA).

Primary Endpoint: Annual rate of moderate to severe exacerbations2

Keep samples on hand to get patients started on TRELEGY

REQUEST SAMPLES
Lung Function

In the landmark IMPACT trial,

TRELEGY significantly improved lung function2 vs FF/VI (an ICS/LABA) and vs UMEC/VI (a LAMA/LABA) in patients with a history of COPD exacerbations

Secondary Endpoint: Change from baseline in trough FEV1 at month 12 vs FF/VI (an ICS/LABA)

FEV1=forced expiratory volume in 1 second

Secondary Endpoint: Change from baseline in trough FEV1 at month 12 vs UMEC/VI (an LAMA/LABA)

FEV1=forced expiratory volume in 1 second

Keep samples on hand to get patients started on TRELEGY

REQUEST SAMPLES
Quality of Life

TRELEGY significantly improved health-related quality of life

in patients with a history of COPD exacerbations

Patients taking TRELEGY were more likely to show an improvement in health-related quality of life total score at 1 year vs FF/VI and vs UMEC/VI as measured by the SGRQ.2,3*

Responder rate* was statistically significantly greater for TRELEGY.2

*Response defined as a decrease in SGRQ total score from baseline of 4 or more. SGRQ for COPD (SGRQ-C) was used and results were then converted to SGRQ for reporting purposes.

SGRQ=St George's Respiratory Questionnaire

Find a TRELEGY representative in your area and request a visit

REQUEST A REP

Stay up-to-date with new information on

trelegy ellipta

Chat